FDA expands Merck antibiotic indication to pneumonia treatment

Jun 04, 2019

The U.S. Food and Drug Administration has approved expanded use of Merck's antibiotic Zerbaxa to treat hospital-acquired pneumonia in patients 18 years and older.

The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections.

According to the FDA, hospital-acquired and ventilator-associated bacterial pneumonia are serious infections that can result in death in some patients. These infections are currently the second most common type of hospital-acquired infection in the United States, according to data from the U.S. Centers for Disease Control and Prevention.

The Zerbaxa indication comes off the heels of a a multinational, double-blind study that compared Zerbaxa to another antibacterial drug in 726 adult patients hospitalized with hospital-acquired and ventilator-associated bacterial pneumonia. The study showed that mortality and cure rates were similar.

Read the full FDA release.

Don't miss your Daily Dose. Sign up to get news like this delivered right to your inbox.